NCT07132801

Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Qualia Life Sciences · Industry
• Sex: All
• Age: 35 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Conditions

• NAD
• NAD+ Levels in the Blood

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Qualia NAD⁺ version 1	Qualia NAD+ version 1 manufactured by Qualia Life Sciences
DIETARY_SUPPLEMENT	Qualia NAD⁺ version 2	Qualia NAD+ version 2 manufactured by Qualia Life Sciences
DIETARY_SUPPLEMENT	Placebo	Rice Flour

Timeline

• Start date: 2025-10-13
• Primary completion: 2025-11-30
• Completion: 2025-12-15
• First posted: 2025-08-20
• Last updated: 2025-08-20

Locations

1 site across 1 country: United States